A decade in psychiatric GWAS research

Tanya Horwitz1 · Katie Lam1 · Yu Chen2 · Yan Xia2 · Chunyu Liu1,2,3

Received: 30 August 2017 / Revised: 29 December 2017 / Accepted: 19 February 2018
© Macmillan Publishers Limited, part of Springer Nature 2018

Abstract
After more than 10 years of accumulated efforts, genome-wide association studies (GWAS) have led to many findings, most of which have been deposited into the GWAS Catalog. Between GWAS’s inception and March 2017, the GWAS Catalog has collected 2429 studies, 1818 phenotypes, and 28,462 associated SNPs. We reclassified the psychology-related phenotypes into 217 reclassified phenotypes, which accounted for 514 studies and 7052 SNPs. In total, 1223 of the SNPs reached genome-wide significance. Of these, 147 were replicated for the same psychological trait in different studies. Another 305 SNPs were replicated within one original study. The SNPs rs2075650 and rs4420638 were linked to the most replications within a single reclassified phenotype or very similar reclassified phenotypes; both were associated with Alzheimer’s disease (AD). Schizophrenia was associated with 74 within-phenotype SNPs reported in independents studies. Alzheimer’s disease and schizophrenia were both linked to some physical phenotypes, including cholesterol and body mass index, through common GWAS signals. Alzheimer’s disease also shared risk SNPs with age-related phenotypes such as age-related macular degeneration and longevity. Smoking-related SNPs were linked to lung cancer and respiratory function. Alcohol-related SNPs were associated with cardiovascular and digestive system phenotypes and disorders. Two separate studies also identified a shared risk SNP for bipolar disorder and educational attainment. This review revealed a list of reproducible SNPs worthy of future functional investigation. Additionally, by identifying SNPs associated with multiple phenotypes, we illustrated the importance of studying the relationships among phenotypes to resolve the nature of their causal links. The insights within this review will hopefully pave the way for future evidence-based genetic studies.

Introduction

The GWAS Catalog is a comprehensive database that archives genome-wide association studies (GWAS) investigating associations between single-nucleotide polymorphisms (SNPs) and a variety of phenotypes, ranging from psychiatric disorders, to physical disorders, to other medical, physical, and psychological traits. GWAS feature data-driven, fairly objective designs and often use relatively large sample sizes, making them better-powered and less biased than most candidate-gene studies.

Motivation behind this review

The year 2017 marks the 10-year anniversary of psychiatric GWAS. While the first GWAS recorded by the GWAS Catalog was published in 2005 on the topic of age-related macular degeneration, A GWAS in the field of psychiatry was not published until a WTCCC-funded study in 2007. This study examined seven diseases, including bipolar disorder [1].

Since then, genotyping costs have dropped dramatically and GWAS have become an essential step on the path towards uncovering genetic factors of phenotypes. Research concerning psychiatric disorders and relevant traits have accounted for a significant share of the accumulated GWAS findings and will be the focus of this review. Such findings are often selectively and mistakenly interpreted by the media, the public, clinicians, patients, and even some investigators in related fields. We feel the obligation to...
provide a scholastic, holistic, and stringent summary of the GWAS data. In doing this, we have identified SNPs that have been repeatedly reported in association with the same disorder and that should thus bear better confidence. We also hope to uncover hidden connections between disorders or traits by highlighting genomic regions that could be associated with multiple conditions, something that can only be done by collecting results from many different studies and reviewing them together.

Candidate genes have been studied for several decades in psychiatry. They have mostly included small sample sizes and have often been underpowered. Some frequently studied genes have been included in meta-analyses combining a large collection of studies. However, such meta-analyses have thus far reported disappointing results. Candidate genes have been found to be non-reproducible or insignificant upon further scrutiny, as in the case of two meta-analyses on bipolar disorder and schizophrenia candidate genes [2, 3]. This article, therefore, focuses on GWAS signals. That being said, as GWAS produce more findings, it will likely be increasingly useful to compare results of candidate genes with GWAS signals. Furthermore, there will be a greater quantity of robust data from which to make more informed decisions about good candidate genes.

It should be noted that, as writing this summary requires some arbitrary decisions regarding inclusion criteria for disorders and traits and grouping of phenotypes, the reported results are somewhat swayed by bias. Its parameters should thus be refined and improved in future reviews.

**Data**

The data in this summary includes all studies recorded by the GWAS Catalog (https://www.ebi.ac.uk/gwas/) as of the date of download (March 30, 2017); the most recent study in the data set was published on October 31st, 2016. The data set includes literature sources, phenotype information, p-values, and identified SNPs, among many other pieces of data.

GWAS utilize stringent significance thresholds as a result of the multiple testing correction needed to account for millions of SNPs on the human genome. While the GWAS Catalog collected SNPs associated with p-values as large as $1 \times 10^{-5}$ (with the exception of one result, which was linked to $2 \times 10^{-5}$), the commonly used cut-off for genome-wide significance is typically $p = 2 \times 10^{-8}$ or $5 \times 10^{-8}$.

The GWAS Catalog, as of the date of download, included a total of 2429 studies, 1818 phenotypes, and 28,462 SNPs. In order to redirect the focus of the analysis to psychiatry, we limited the set of phenotypes to a list of 217 Table 1

| Total # of SNPs | # of Genome-wide significant SNPs | # of Replicated SNPs |
|----------------|----------------------------------|---------------------|
| 28,462         | 8740                             |                     |

Also listed are the SNPs found in more than one study that reached genome-wide significance in at least one of the studies (Supplementary Table 2a) and those which were significant for multiple samples within the same study but were not listed in Supplementary Table 2a for that phenotype (Supplementary Table 2b).
reclassified phenotypes, many of which are also directly related to psychiatric illness (Supplementary Table 1). In addition to retaining many phenotypes from the initial data set, we added some broader phenotypes that combined similar traits in order to make parsing and comparison easier and more efficient. While many of the reclassified phenotypes are explicitly psychological in nature, we also included phenotypes that are not classically psychological but are likely related to or correlated with mental functioning. A total of 514 studies and 7052 unique SNPs remained after phenotype recategorization and filtering. Out of these, 1223 SNPs reached genome-wide significance. Of these, 453 SNPs were reproduced in some capacity (see section on reproducibility and Table 1).

Finally, the data set included a broad range of samples. The paper with the smallest sample size among the psychiatry-related studies was a study on clozapine-induced cytotoxicity that used 90 European ancestry lymphoblast cell lines [4]. The largest sample size included samples from 549,935 individuals as part of a study on depression, neuroticism, and subjective well-being [5].

Reproducibility

As in any other scientific discipline, reproducibility is a critical indication of the strength of genetic findings. Here, we identified SNPs that have been associated with the same reclassified disorder or trait in two or more studies (if a significant association was found for a very similar phenotype at that SNP, that phenotype was also included). If the specific risk allele for the SNPs of interest were reported consistently for each study, we also included the allele (denoted by a hyphen and the base letter following the name of the SNP). We excluded non-identical reclassified “compound phenotypes” (phenotypes that are a combination of multiple disorders or traits) if they only matched with reclassified phenotypes that were part of the compound. For example, if the only reclassified phenotypes found to be significant for a SNP were schizophrenia and the compound phenotype “autism, bipolar disorder, or schizophrenia,” then the SNP was not considered to be replicated. However, a SNP found to be related to the phenotype psychosis and mood in two different studies would be considered replicated. Furthermore, we required at least one of the findings corresponding to the phenotype and SNP to reach genome-wide significance ($p \leq 2 \times 10^{-8}$). All further replicated findings for the same SNP and the same or very similar reclassified phenotype met the catalog’s $p$-value cut-off of $p \leq 2 \times 10^{-3}$. In Supplementary Table 2a, we listed the 147 SNPs meeting the above criteria (excluding replication samples within a single paper) for reclassified phenotypes. Supplementary Table 2b lists 305 SNPs that were significantly replicated in samples within a single paper but were not listed in Supplementary Table 2a for that/those phenotype(s).

We consider the 147 SNPs reported by two or more separate publications arguably more reliable than the 305 SNPs replicated by the same publications, so our discussion focuses on the former. The SNPs rs2075650 and rs4420638 were linked to the most replications within a single reclassified phenotype. Both are associated with AD and cognitive decline, also brain eQTL (Supplementary Table 2a).

rs2075650 is located in an intron of the TOMM40 gene, a mitochondria membrane protein. It is a brain eQTL SNP for the gene PP1M1N and many other genes (though not for APOE or TOMM40). The G-allele for rs2075650 was reported to confer an odds ratio of two in a small case–control study [6]. This SNP is also associated with hippocampal atrophy. However, there is a question as to whether it carries an independent AD risk. One study posits that rs2075650’s relationship with AD is more attributable to its modest linkage disequilibrium with rs429358 [7]. rs429358 is on the fourth exon of APOE and, along with rs7412, determines the APOE haplotype, where the variant e4 is the strongest risk factor for AD. rs429358 was associated with AD in three studies (Supplementary Table 2a). The SNP rs4420638 is located downstream of the APOC1 gene. rs4420638’s association with AD could also be related to its linkage disequilibrium with rs429358 and so is likely also not an entirely independent risk locus [8, 9]. rs4420638 is a brain eQTL SNP for non-APOE genes, according to BRAINEAC. The often complex relationships among GWAS signal linkage disequilibrium and the link between GWAS signals and brain eQTL may merit further investigation to clarify issues of causality.

Narcolepsy and nicotine-related phenotypes were also linked to highly replicated SNPs. They were associated with the SNPs rs1154155 [10–13] and rs1051730 [14–17], respectively, each in four different studies. rs1154155 is mapped to the downstream region of TRAJ10, a gene in the TRAJ (T cell receptor alpha joining) gene cluster. rs1154155 is an eQTL SNP for mir208a in white matter. rs1051730 is a coding synonymous variant in CHRNA3 but is also an eQTL SNP for CHRNA5 in brain. Both CHRNA3 and CHRNA5 are strong candidates for nicotine dependence.

Schizophrenia was the disease with by far the largest number of SNPs replicated within-phenotype—74—though many of these replications came from the same two studies, which shared samples [18, 19]. Educational attainment accounted for eight replicated SNPs, and Alzheimer’s disease was associated with 21 replicated SNPs.

While, at face value, the aforementioned findings could suggest strong genetic underpinnings of Alzheimer’s...
disease and schizophrenia, it should be noted that some topics have been given more attention than others. For example, the search term “GWAS Alzheimer’s disease” returns about four times as many results in Google Scholar as “GWAS educational attainment.”

The fact that some studies drew from the same samples as other studies must also be taken into account. For example, only four publications from two research groups (from the Netherlands and the UK) have studied educational attainment in GWAS [20–23], and many of the samples from the four studies either were shared or came from the same biobank. Because recruiting huge samples is difficult, it is common for consortia to publish several studies on the same continuously growing sample. Thus, not all of the SNPs we recorded should be considered independently replicated. Going forward, it will be important for researchers to be cognizant of the limited validity of many reported GWAS findings.

Table 1 summarizes the quantity of SNPs according to criteria of significance, phenotype class, and replication status.

**Reproduced GWAS signals as brain eQTL**

We entered the 147 reproduced GWAS signals into the UK Brain Expression Consortium’s (UKBEC) expression quantitative trait loci (eQTL) database (http://www.braineac.org/). Among the 147 SNPs, a total of 88 SNPs (60%) exceeded the threshold cut-off required to reach significance (0.05/147 replicated SNPs = 3.4 × 10⁻⁴, see Supplementary Table 2a). Of these, the SNP rs17693963 (associated with schizophrenia, bipolar disorder, or schizoaffective disorder [24, 25]) was the strongest brain eQTL and was most significantly associated with expression of the gene ZNF389 in white matter (p = 2.8 × 10⁻¹⁰), among other brain regions. GTEx data also reported rs17693963 as an eQTL SNP in many tissues (including brain) and as being associated with several genes. The second most significant brain eQTL was rs727428 (associated with sex hormones and androgen levels [26, 27]). This SNP was most strongly associated with TNFSF13, TNFSF12-13, and TNFSF12 in temporal cortex (p = 2.1 × 10⁻⁹) and cerebellum (p = 4.7 × 10⁻⁹).

**Cross-phenotype analysis**

GWAS can help draw attention to psychiatric disorders and other intermediate phenotypes that may share genomic risk factors. The literature with the greatest impact on this topic has largely pointed to overall shared genetics between schizophrenia and other psychiatric conditions, perhaps most notably bipolar disorder, intellectual disability, and autism spectrum disorder, based on polygenic risk scores and shared rare variants [19, 28–30]. In this analysis, we again focused on individual SNPs recorded in the GWAS Catalog, which primarily includes common variants. For cases in which phenotypes were redundant, they were sometimes summarized or combined (e.g., “hematocrit” and “red blood cell traits,” when linked to the same SNP, were condensed to “red blood cell traits”).

We identified the SNPs and SNP risk alleles mapped to distinct phenotypes (e.g., excluding matches between single phenotypes and compound phenotypes encapsulating that phenotype and excluding very similar phenotypes). The cross-phenotype analysis required a more stringent threshold cut-off than the reproducibility analysis because, unlike in the case of reproducibly, this analysis needed to account for all examined phenotypes. We thus required that the associations for all phenotypes reach genome-wide significance (p ≤ 2 × 10⁻⁸).

Because our focus is on psychiatry, we only summarized findings concerning SNPs linked to at least one psychological, behavioral, or cognitive trait, though we also included all significant findings for non-psychological/behavioral/cognitive phenotypes that were associated with the same SNPs. The SNPs associated with multiple phenotypes are plotted in a network in Fig. 1.

**Addictive behavior and substance use**

Many significant SNPs were mapped to the use of various substances, a phenotype category that has been measured in both controls and those affected by addiction. Four SNPs were associated with both nicotine-related phenotypes and phenotypes related to respiration. rs1051730 was linked to smoking behavior [15–17] and nicotine dependence [14] (combined into “nicotine-related phenotypes”), post bronchodilator FEV1, post bronchodilator FEV1/FVC ratio, pre bronchodilator FEV1, pre bronchodilator FEV1/FVC ratio, and lung cancer [31, 32, 34]; rs2036527 was related to smoking behavior [33], post bronchodilator FEV1, post bronchodilator FEV1/FVC ratio, pre bronchodilator FEV1, pre bronchodilator FEV1/FVC ratio, and lung cancer [31, 32, 34]; rs4684276-A was associated with post bronchodilator FEV1, post bronchodilator FEV1/FVC ratio [34], and nicotine dependence [35]; and rs56113850-T was associated with nicotine metabolite ratio in current smokers [36], local histogram emphysema pattern [37], post bronchodilator FEV1, and post bronchodilator FEV1/FVC ratio [34]. While these connections between smoking and respiratory phenotypes are meaningful, there exists the strong possibility that respiratory changes are the product of smoking and that these SNPs are not organic genetic causes of lung cancer.

Additionally, rs6265 was associated with both body mass index [38] and smoking behavior [15].
Alcohol use also shared common risk SNPs with many other disorders and traits, particularly those related to the circulatory and digestive systems. One meta-analysis of “maxdrinks,” an alcohol-related phenotype measuring the greatest number of drinks that an individual has ever consumed in a 24-h period, included the results of two studies [39]. While neither of the two studies yielded a statistically significant association for rs1229984, the SNP achieved a \( p \)-value of \( 2.04 \times 10^{-8} \) for the meta-analysis. Two other studies, one on alcohol dependence [40] and the other on the effects of alcohol and smoking on esophageal cancer risk [41], found evidence for rs1229984 as a risk SNP. Further, this SNP was found to be linked to oral cavity and pharyngeal cancer [42], rs671 was associated with drinking behavior [43], coronary heart disease [44], alcohol consumption (maxdrinks) and response to alcohol consumption (flushing) in small samples of Han Chinese participants [45], esophageal cancer [46], serum alpha-antitrypsin levels [47], body mass index [47], mean corpuscular hemoglobin concentration [48], serum creatinine [49], and hematological and biochemical traits [48]. A study assessing Han Chinese drinkers and nondrinkers [50] identified rs11066280, a SNP also associated with blood pressure phenotypes [51–53], esophageal cancer [54], coronary heart disease [55], thoracic-to-hip circumference ratio [56], metabolite levels [57], and triglycerides [58], in other studies. The SNP rs1800562 was associated with transferrin glycosylation [59], which is relevant to alcohol consumption, as well as with iron status biomarkers [60–62], hematological parameters [63], hepcidin levels [64], cardiovascular-disease risk factors [65], cholesterol [66, 67], hemoglobin [68–70], and red blood cell traits [68, 71]. rs1229654 was linked to body mass index [47], glycemic traits [72], HDL cholesterol, gamma glutamyl transpeptidase [57], and alcohol consumption [73]. rs2074356 was linked to alcohol consumption [73], gamma glutamyl transpeptidase, HDL cholesterol [57], esophageal cancer [54], glycemic traits [72], biomedical quantitative traits [74], and renal function-related traits (BUN) [49], and rs3811647 was linked to hepcidin levels [64], iron status biomarkers [60, 75, 76], alcohol consumption (transferrin glycosylation) [59], and hereditary hemochromatosis-related traits (HFE mutation homozygotes) [77].

Coffee consumption [78, 79] shared a genome-wide association with diastolic blood pressure [80] at rs6495122-A and with blood metabolite levels [81] at rs6968554-A.

According to research that has been conducted thus far, SNPs mapped to the use of substances overlap almost exclusively with SNPs related to physical, non-psychological phenotypes, which could either reflect the
physical consequences of excessive substance use or indicate common genetic predispositions. Surprisingly, there were no significant associations between substance use phenotypes and psychiatric disorders that are frequently comorbid with substance abuse.

**Educational attainment**

Findings pertaining to educational attainment also appeared multiple times in cross-phenotype analysis. The term “educational attainment” had multiple implications. For example, “educational attainment” could indicate years of education or performance on a reasoning task, which are quite distinct from each other. rs10761741-T has been identified as a SNP risk allele for vascular endothelial growth factor levels [82] and years of education [20]. In the case of the former, the T allele at this locus seemed to indicate greater epinephrine-induced platelet aggregation and higher circulating VEGF levels. Serum VEGF levels have been reported as being associated with prefrontal cortex volume in schizophrenia patients [83]. Therefore, there is a possibility that this SNP might be related to educational attainment as a result of its contribution to brain structure.

rs2456973 was associated with vitiligo [84], a skin disorder, and educational attainment [20]. There is no obvious genetic connection between the two phenomena so far.

One meta-analysis reported rs12193446-A as the strongest SNP risk allele for refractive error × education interaction [85]. Another study also revealed rs12193446-A as the SNP allele most strongly determining ocular axial length [86]. Similarly, a study of a rural population in India reported a positive correlation between ocular axial length and education; the same result was found in two other studies—one with a Chinese population and one with an elderly White population [87–89].

The SNP rs12553324 was found to be associated with level of educational attainment [23] and, in a separate study, was also identified as an area of interest for bipolar disorder [90]. Glahn et al., in a non-genetic 2006 study predating both of the former, found that bipolar patients had fewer years of educational attainment [91]. On the contrary, when measuring academic achievement in terms of performance rather than years in school, MacCabe et al. found somewhat mixed results [92]. While there was a relationship between bipolar disorder and low grades, there was also a very increased rate of eventual bipolar disorder diagnosis amongst those with high grades, compared to those with average grades. A genetic study reported a positive genetic correlation, achieved through linkage disequilibrium score regression, between bipolar disorder and years of education [93]. One paper studying polygenic risk score results, which represent combined contribution of many common SNPs to risk, found that high risk score of bipolar disorder and schizophrenia are predictive of high educational attainment [94]. There appears to be a relationship between bipolar disorder and educational attainment; the specific nature of this link should be further studied.

**Alzheimer’s disease**

Several studies mapped common SNPs to Alzheimer’s disease and many other phenotypes [7, 9, 58, 65–67, 95–143]. More than one SNP was mapped to both Alzheimer’s disease and each of the following traits:

- Verbal declarative memory
- Cingulate cortical amyloid beta load (covariate in one study)
- C-reactive protein
- Longevity
- Cholesterol
- Cognitive decline
- Age-related macular degeneration
- Triglycerides

Given that both Alzheimer’s disease and these phenotypes are largely related to aging, the findings are not surprising. Inflammation, as it relates to Alzheimer’s, could also be an interesting further topic of study because of inflammation’s link to C-reactive protein.

**Schizophrenia**

Schizophrenia-focused GWAS findings also attained cross-phenotype significance. In particular, rs13107325-T was linked to schizophrenia [18], as well as to body mass index [112, 144, 145], HDL cholesterol [66, 67], blood pressure [146, 147], and N-terminal pro b-type natriuretic peptide in acute coronary syndrome [148]. Some of these findings are congruent with research that has found higher rates of cardiovascular diseases in schizophrenia [149, 150]. rs8042374 was associated with schizophrenia [18, 19] and lung cancer [151], a finding that is not incredibly surprising given the high rates of smoking in schizophrenics [152].

While some SNPs associated with both schizophrenia only and cohorts with schizophrenia and other disorders (e.g., autism, bipolar disorder) were excluded from the results due to the complications of linking a compound trait to a single finding, the high volume of SNPs associated with such combined effects suggests heretofore uncovered genetic commonalities between schizophrenia and other psychiatric disorders. Although polygenic analysis indicates that bipolar disorder and schizophrenia share genetic risk factors, they did not share any significant individual SNP associations according to our analysis. This may be related to imbalance in sample sizes. Schizophrenia GWAS
typically have much larger sample sizes than bipolar disorder GWAS. Still, there was some evidence for shared GWAS signals between the two disorders. For example, the SNP rs1006737 in the CACNA1C gene was linked to schizophrenia, with a $p = 5 \times 10^{-12}$, but with bipolar disorder at $p = 7 \times 10^{-8}$ [153, 154]. Thus, the bipolar association did not meet the significance threshold for our analysis. However, both schizophrenia and bipolar disorder were associated with several different SNPs reaching genome-wide significance in CACNA1C [18, 19, 153, 155].

Supplementary Table 3 summarizes the cross-phenotype SNPs and their associated phenotypes, with the phenotypes that were later transformed into reclassified phenotypes listed under the name of the reclassified phenotype.

**Limitations of the current review**

We acknowledge that there are many areas of GWAS that were not deeply addressed within this paper. In writing this review, we relied primarily on the data as it was presented in the GWAS Catalog. Certain statistical parameters such as effect size could not be easily summarized and compared, as not all studies used the same criteria. Also, as the GWAS Catalog includes only GWAS, our analysis did not take candidate gene studies into account, meaning that our points of comparison were not exhaustive.

The present review is intended to serve as a broad summary and analysis of psychiatric GWAS. We believe that future studies and reviews that approach GWAS from a different angle or that focus on finer statistical details, even going so far as to scrutinize raw data from individuals, could lead to interesting and important findings.

**More validation is needed**

As shown in Table 1, fewer than half of the psychological genome-wide-significant associations have been validated, either in an independent study or in a replication sample. Because of the possibility of false discovery, the likelihood of a GWAS signal being a true marker of the tested phenotype holds fairly limited promise prior to replication.

**Heterogeneity issues across studies**

Any discrepancies between individual studies must be taken into consideration as confounding variables. For example, studies included a broad range of sample sizes, some of which only included a single racial or ethnic group; these studies should be replicated with different populations. It should also be noted that some studies drew from the same consortia, meaning that many samples likely shared participants. Additionally, some of the papers in the database were meta-analyses of other GWAS, which created another opportunity for sample overlaps.

**Differentiating causal associations from indirect correlational relationships**

In assessing the data, it is important to beware of tempting but potentially false causal conclusions. For example, rs1051730 was mapped to smoking and some related physical conditions, including lung cancer. In order to find evidence that the listed physical health risks are governed by the same genomic regions (rather than just being a result of smoking behavior), it would be important to compare smokers to non-smokers, a variable that was not stringently controlled with respect to the loci of interest.

Despite these caveats, the relationships drawn between non-pathological phenotypes and psychiatric disorders is an important area of study. The findings linking the two types of traits promote the idea that physical phenotypes may eventually be able to serve as valid biomarkers of psychopathology. Going forward, it will be important to make efforts to distinguish between shared genetic roots and phenotypes that co-occur but which are not the results of a common genetic cause.

**Conclusion**

GWAS research has yielded many discoveries in both psychiatry and physical pathology. Further research and improvement in big data parsing methods will be an imperative part of fully legitimizing the field, but there already exist strong bases for forming theories about genome-wide associations.

Most psychiatric disorders appear to share specific risk loci with physical disorders or phenotypes instead of other behavioral, psychological, or cognitive traits. This could perhaps be because many psychiatric disorders are characterized by a rather wide assortment of sub-phenotypes, some of which may be linked to different biological phenotypes. Perhaps most notably, GWAS research on substance use has led to many associations with physical traits, which may harbor implications for addiction research.

**Future directions**

Revealing the functionality of GWAS-associated SNPs and resolving the causal nature of the relationship between SNPs and their associated traits should be one of the major objectives of post-GWAS conducted in the coming years. The CRISPR/Cas9 editing of risk alleles in induced pluripotent stem cells (iPSC) [156], as well as gene knockdown
and knockout studies, promise to bring exciting new insights to the discipline of GWAS.

The study of genetic relationships between various phenotypes is a vast new field of research with possibilities that will only increase as the rate of research accelerates and the GWAS database grows. Such research is giving us a new perspective on the etiology and pathology of disorders.

GWAS, while still in its infancy, has led to a prodigious quantity of publications and areas of study. We hope the insights gleaned in this investigation will help to guide future research in psychiatric genomics by highlighting worthwhile areas of investigation, ultimately enhancing our understanding of psychiatric disorders.

Acknowledgements We thank Dr. Elliot S. Gershon for valuable discussions and comments.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest

References

1. Wellcome Trust Case Control C. Genome-wide association study of 14,000 cases of seven common diseases and 3000 shared controls. Nature. 2007;447:661–78.
2. Seifuddin F, Mahon PB, Judy J, Pirooznia M, Jancic D, Taylor J, et al. Meta-analysis of genetic association studies on bipolar disorder. Am J Med Genet B Neuropsychiatr Genet. 2012;159B:508–18.
3. Farrell MS, Werge T, Sklar P, Owen MJ, Ophoff RA, O’Donovan MC, et al. Evaluating historical candidate genes for schizophrenia. Mol Psychiatry. 2015;20:555–62.
4. de With SA, Pulit SL, Wang T, Staal WG, de Bakker PI, et al. Genome-wide association study of lymphoblast cell viability after clozapine exposure. Am J Med Genet B Neuropsychiatr Genet. 2015;168B:116–22.
5. Okbay A, Basilmann BM, De Neve JE, Turley P, Nivard MG, Fontana MA, et al. Genetic variants associated with subjective well-being, depressive symptoms, and neuroticism identified through genome-wide analyses. Nat Genet. 2016;48:624–33.
6. Potkin SG, Guffanti G, Lakatos A, Turner JA, Krugel F, Fallon JH, et al. Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer’s disease. PLoS ONE. 2009;4:e6501.
7. Deelen J, Beekman M, Uh HW, Helmer Q, Kuningas M, Christiansen L, et al. Genome-wide association study identifies a major locus for converting to survival in old age: the APOE locus revisited. Aging Cell. 2011;10:686–98.
8. Nyholt DR, Yu CE, Visscher PM. On Jim Watson’s APOE status: genetic information is hard to hide. Eur J Hum Genet. 2009;17:147–9.
9. Coon KD, Myers AJ, Craig DW, Webster JA, Pearson JV, Lince DH, et al. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer’s disease. J Clin Psychiatry. 2007;68:613–8.
10. Hor H, Kutalik Z, Dauvilliers Y, Valsesia A, Lammers GJ, Donjacour CE, et al. Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy. Nat Genet. 2010;42:786–9.
11. Hallmayer J, Faraco J, Lin L, Hesselson S, Winkelmann J, Kawashima M, et al. Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet. 2009;41:708–11.
12. Toyoda H, Miyagawa T, Koike A, Kanbayashi T, Imanishi A, Sagawa Y, et al. A polymorphism in CCR1/CCR3 is associated with narcolepsy. Brain Behav Immun. 2015;49:148–55.
13. Han F, Faraco J, Dong XS, Olilia HM, Lin L, Li J, et al. Genome-wide analysis of narcolepsy in China implicates novel immune loci and reveals changes in association prior to versus after the 2009 H1N1 influenza pandemic. PLoS Genet. 2013;9:e1003880.
14. Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature. 2008;452:638–42.
15. Tobacco, Genetics C. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat Genet. 2010;42:441–7.
16. Thorgeirsson TE, Gudbjartsson DF, Surakka I, Vink JM, Amin N, Geller F, et al. Sequence variants at CHRNA3–CHRNB4 and CYP2A6 affect smoking behavior. Nat Genet. 2010;42:448–53.
17. Liu JZ, Tozzi F, Waterworth DM, Pillai SG, Muglia P, Middleton L, et al. Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet. 2010;42:436–40.
18. Goes FS, McGrath J, Avramopoulos D, Wolyniec P, Pirooznia M, Ruczinski I, et al. Genome-wide association study of schizophrenia in Ashkenazi Jews. Am J Hum Genet. 2008;83:649–59.
19. Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421–7.
20. Okbay A, Beauchamp JP, Fontana MA, Lee JJ, Pers TH, Rietveld CA, et al. Genome-wide association study identifies 74 loci associated with educational attainment. Nature. 2016;533:539–42.
21. Rietveld CA, Medland SE, Derringer J, Yang J, Esko T, Martin NW, et al. GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. Science. 2013;340:1467–71.
22. Rietveld CA, Esko T, Davies G, Pers TH, Turley P, Benyamin B, et al. Common genetic variants associated with cognitive performance identified using the proxy-phenotype method. Proc Natl Acad Sci USA. 2014;111:13790–4.
23. Davies G, Marioni RE, Liewald DC, Hill WD, Hagenaars SP, Harris SE, et al. Genome-wide association study of cognitive functions and educational attainment in UK Biobank (N=112,151). Mol Psychiatry. 2016;21:758–67.
24. Sleiman P, Wang D, Glessner J, Hadley D, Gurr RE, Cohen N, et al. GWAS meta analysis identifies TSNARE1 as a novel schizophrenia/bipolar susceptibility locus. Sci Rep. 2013;3:3075.
25. Rudelrrer DM, Fanous AH, Ripke S, McQuillin A, Amour RL, Schizophrenia Working Group of the Psychiatric Genomics C. et al. Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia. Mol Psychiatry. 2014;19:1017–24.
26. Jin G, Sun J, Kim ST, Feng J, Wang Z, Tao S, et al. Genome-wide association study identifies a new locus JMJ1D1 at 10q21 that may influence serum androgen levels in men. Hum Mol Genet. 2012;21:5222–8.
27. Prescott C, Thompson DJ, Kraft P, Chanock SJ, Audley T, Brown J, et al. Genome-wide association study of circulating estradiol, testosterone, and sex hormone-binding globulin in postmenopausal women. PLoS ONE. 2012;7:e37815.
A decade in psychiatric GWAS research

28. Cross-Disorder Group of the Psychiatric Genomics C, Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet. 2013;381:1371–9.

29. International Schizophrenia C, Purcell SM, Wray NR, Stone JL, Visscher PM, O’Donovan MC, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;460:748–52.

30. Li J, Cai T, Jiang Y, Chen H, He X, Chen C, et al. Genes with de novo mutations are shared by four neuropsychiatric disorders discovered from NPdenovo database. Mol Psychiatry. 2016;21:290–7.

31. Landi MT, Chatterjee N, Yu K, Goldin LR, Goldstein AM, Cross-Disorder Group of the Psychiatric Genomics C, International Schizophrenia C, Purcell SM, Wray NR, Stone JL, et al. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet. 2013;381:1371–9.

32. McKay JD, Hung RJ, Gaborieau V, Boffetta P, Chabrier A, Byrnes G, et al. Lung cancer susceptibility locus at 5p15.33. Nat Genet. 2008;40:1404–6.

33. David SP, Hamidovic A, Chen GK, Bergen AW, Wessel J, McKay JD, Hung RJ, Gaborieau V, Boffetta P, Chabrier A, Byrnes G, et al. Lung cancer susceptibility locus at 5p15.33. Nat Genet. 2008;40:1404–6.

34. Lutz SM, Cho MH, Young K, Hersh CP, Castaldi PJ, McDonald ML, et al. A genome-wide association study identifies risk loci for spirometric measures among smokers of European and African ancestry. BMC Genet. 2015;16:138.

35. Hancock DB, Regimsoon GW, Gaddy NC, Chen X, Saccone NL, Lutz SM, et al. Genome-wide meta-analysis reveals common splice site acceptor variant in CHRNA4 associated with nicotine dependence. Trans Psychiatry. 2015;5:e651.

36. Patel YM, Park SL, Han Y, Wilkens LR, Bickellower H, Rosenberger A, et al. Novel association of genetic markers affecting CYP2A6 activity and lung cancer risk. Cancer Res. 2016;76:5768–76.

37. Castaldi PJ, Cho MH, San Jose Estepar R, McDonald ML, Laird N, Beatty TH, et al. Genome-wide association study identifies regulatory loci associated with distinct local histogram emphysema patterns. Am J Respir Crit Care Med. 2014;190:399–409.

38. Thörleifsson G, Walters GB, Gudbjartsson DF, Steinthorsdottir V, Sulem P, Helgadottir A, et al. Genome-wide association study yields new sequence variants at seven loci that associate with measures of obesity. Nat Genet. 2009;41:18–24.

39. Kapoor M, Wang JC, Wetherill L, Le N, Bertelsen S, Hinrichs AL, et al. A meta-analysis of two genome-wide association studies to identify novel loci for maximum number of alcoholic drinks. Hum Genet. 2013;132:1141–51.

40. Park BL, Kim JW, Cheong HS, Kim LH, Lee BC, Seo CH, et al. Extended genetic effects of ADH cluster genes on the risk of alcohol dependence: from GWAS to replication. Hum Genet. 2013;132:657–68.

41. Cui R, Kamatani Y, Takahashi A, Usami M, Hosono N, Kawaguchi T, et al. Functional variants in ADH1B and ALDH2 coupled with alcohol and smoking synergistically enhance esophageal cancer risk. Gastroenterology. 2009;137:1768–75.

42. McKay JD, Truong T, Gaborieau V, Chabrier A, Chuang SC, Byrnes G, et al. A genome-wide association study of upper aerodigestive tract cancers conducted within the INHANCE consortium. PLoS Genet. 2011;7:e1001333.

43. Takeuchi F, Isono M, Nabika T, Katsuya T, Sugiyama T, Yamaguchi S, et al. Confirmation of ALDH2 as a major locus of drinking behavior and of its variants regulating multiple metabolic phenotypes in a Japanese population. Circ J. 2011;75:911–8.

44. Takeuchi F, Yokota M, Yamamoto K, Nakashima E, Katsuya T, Asano H, et al. Genome-wide association study of coronary artery disease in the Japanese. Eur J Hum Genet. 2012;20:333–40.

45. Quillen EE, Chen XD, Almasy L, Yang F, He H, Li X, et al. ALDH2 is associated to alcohol dependence and is the major genetic determinant of “daily maximum drinks” in a GWAS study of an isolated rural Chinese sample. Am J Med Genet B Neuropsychiatr Genet. 2014;165B:103–10.

46. Setoh K, Tero C, Muro S, Kawaguchi T, Tabara Y, Takahashi M, et al. Three missense variants of metabolic syndrome-related genes are associated with alpha-1 antitrypsin levels. Nat Commun. 2015;6:7754.

47. Wen W, Zheng W, Okada Y, Takeuchi F, Tabara Y, Hwang JY, et al. Meta-analysis of genome-wide association studies in East Asian-ancestry populations identifies four new loci for body mass index. Hum Mol Genet. 2014;23:5492–504.

48. Kamatani Y, Matsuda K, Okada Y, Kubo M, Hosono N, Daito Y, et al. Genome-wide association study of hematological and biochemical traits in a Japanese population. Nat Genet. 2010;42:210–5.

49. Okada Y, Sim X, Go MJ, Wu JY, Gu D, Takeuchi F, et al. Meta-analysis identifies multiple loci associated with kidney function-related traits in east Asian populations. Nat Genet. 2012;44:904–9.

50. Yang X, Lu X, Wang L, Chen S, Li J, Cao J, et al. Common variants at 12q24 are associated with drinking behavior in Han Chinese. Am J Clin Nutr. 2013;97:545–51.

51. Kato N, Takeuchi F, Tabara Y, Kelly TN, Go MJ, Sim X, et al. Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. Nat Genet. 2011;43:531–8.

52. Lu X, Wang L, Lin X, Huang J, Charles Gu C, He M, et al. Genome-wide association study in Chinese identifies novel loci for blood pressure and hypertension. Hum Mol Genet. 2015;24:865–74.

53. Kato N, Loh M, Takeuchi F, Verweij N, Wang X, Zhang W, et al. Trans-ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation. Nat Genet. 2015;47:1282–93.

54. Wu C, Hu Z, He Z, Jia W, Wang F, Zhou Y, et al. Genome-wide association study identifies three new susceptibility loci for esophageal squamous-cell carcinoma in Chinese populations. Nat Genet. 2011;43:679–84.

55. Lu X, Wang L, Chen S, He L, Yang X, Shi Y, et al. Genome-wide association study in Han Chinese identifies four new susceptibility loci for coronary artery disease. Nat Genet. 2012;44:890–4.

56. Cha S, Park AY, Kang C. A genome-wide association study uncovers a genetic locus associated with thoracic-to-hip ratio in Koreans. PLoS ONE. 2015;10:e0145220.

57. Kim YJ, Go MJ, Hu C, Hong CB, Kim YK, Lee JY, et al. Large-scale genome-wide association studies in East Asians identify new genetic loci influencing metabolic traits. Nat Genet. 2011;43:990–5.

58. Lu X, Huang J, Mo Z, He J, Wang L, Yang X, et al. Genetic susceptibility to lipid levels and lipid change over time and risk of incident hyperlipidemia in Chinese populations. Circ Cardiovasc Genet. 2016;9:37–44.

59. Kutalik Z, Benyamin B, Bergmann S, Mooser V, Waerger B, Montgomery GW, et al. Genome-wide association study identifies two loci strongly affecting transferrin glycosylation. Hum Mol Genet. 2011;20:3710–7.

60. Benyamin B, McRae AF, Zhu G, Gordon S, Henders AK, Palotie A, et al. Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels. Am J Hum Genet. 2009;84:60–65.
61. Benyamin B, Ferreira MA, Willemsen G, Gordon S, Middelberg RP, McEvoy BP, et al. Common variants in TMPRSS6 are associated with iron status and erythrocyte volume. Nat Genet. 2009;41:1173–5.

62. Benyamin B, Eskin T, Ried JS, Radhakrishnan A, Vermeulen SH, Traglia M, et al. Novel loci affecting iron homeostasis and their effects in individuals at risk for hemochromatosis. Nat Commun. 2014;5:4926.

63. Soranzo N, Spector TD, Mangino M, Kuhnel B, Rendon A, Teumer A, et al. A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet. 2009;41:1182–90.

64. Traglia M, Girelli D, Bimo G, Camporini N, Corbella M, Sala C, et al. Association of HFE and TMPRSS6 genetic variants with iron and erythrocyte parameters is only in part dependent on serum hepcidin concentrations. J Med Genet. 2011;48:629–34.

65. Middelberg RP, Ferreira MA, Henders AK, Heath AC, Madden PA, Montgomery GW, et al. Genetic variants in LPL, OASL and TOMM40/APOE-C1-C2-C4 genes are associated with multiple cardiovascular-related traits. BMC Med Genet. 2011;12:132.

66. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, St [...] 22 loci that influence erythrocyte phenotypes in the CHARGE Consortium. Nat Genet. 2009;41:1191–8.

67. Li J, Glesnner JT, Zhang H, Hou C, Wei Z, Bradfield JP, et al. GWAS of blood cell traits identifies novel associated loci and epistatic interactions in Caucasian and African-American children. Hum Mol Genet. 2013;22:1457–64.

68. Soranzo N, Sanna S, Wheeler E, Gieger C, Radke D, Dupuis J, et al. Common variants at 10 genomic loci influence hemoglobin A1C levels via glycosylc and nonglycemic pathways. Diabetes. 2010;59:3229–39.

69. Kullo IJ, Ding K, Jouni H, Smith CY, Chute CG. A genome-wide association study of Asian populations uncovers genetic factors influencing eight quantitative traits. Nat Genet. 2009;41:527–34.

70. McLaren CE, Garner CP, Constantine CC, McLachlan S, Vulpe CD, Snively BM, et al. Genome-wide association study identifies genetic loci associated with iron deficiency. PLoS ONE. 2011;6:e17390.

71. Pichler I, Minelli C, Sanna S, Tanaka T, Schwienbacher C, Naitza S, et al. Identification of a common variant in the TFR2 gene implicated in the physiological regulation of serum iron levels. Hum Mol Genet. 2011;20:1232–40.

72. de Tayrac M, Roth MP, Jouanolle AM, Coppin H, le Gac G, Piperno A, et al. Genome-wide association study identifies TF as a significant modifier gene of iron metabolism in HFE hemochromatosis. J Hepatol. 2015;62:664–72.

73. Amin N, Byrne E, Johnson J, Chenexiv-Trench G, Walter S, Nolte IM, et al. Genome-wide association analysis of coffee drinking suggests association with CYP1A1/CYP1A2 and NR2C1. Mol Psychiatry. 2012;17:1116–29.

74. Coffee Caffeine Genetics C, Cornelis MC, Byrne EM, Esko T, Nalls MA, et al. Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption. Mol Psychiatry. 2015;20:647–56.

75. Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, et al. Genome-wide association study of blood pressure and hypertension. Nat Genet. 2009;41:677–87.

76. Shin SY, Fauman EB, Petersen AK, Krumsiek J, Santos R, Huang J, et al. An atlas of genetic influences on human blood metabolites. Nat Genet. 2014;46:543–50.

77. Choi SH, Ruggiero D, Sorice R, Song C, Nutile T, Vernon Smith A, et al. Six novel loci associated with circulating VEGF levels identified by a meta-analysis of genome-wide association studies. PLoS Genet. 2016;12:e1005874.

78. Pillai A, Howell KR, Ahmed AO, Weinberg D, Allen KM, Bruggemann J, et al. Association of serum VEGF levels with prefrontal cortical volume in schizophrenia. Mol Psychiatry. 2016;21:686–92.

79. Jin Y, Birllea SA, Fain PR, Ferrara TM, Ben S, Riccardi SL, et al. Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet. 2012;44:676–80.

80. Fan Q, Verhoeven VJ, Wojciechowski R, Barathi VA, Hysgi PG, Guggenheim JA, et al. Meta-analysis of gene-environment-wide association scans accounting for education level identifies additional loci for refractive error. Nat Commun. 2016;7:11008.

81. Cheng CY, Schache M, Ikram MK, Young TL, Guggenheim JA, Vitart V, et al. Nine loci for ocular axial length identified through genome-wide association studies, including shared loci with refractive error. Am J Hum Genet. 2013;93:264–77.

82. Nangia V, Jonas JB, Sinha A, Matic A, Kulkarni M, Panda-Jonas S. Ocular axial length and its associations in an adult population of central rural India: the Central India Eye and Medical Study. Ophthalmology. 2010;117:1360–6.

83. Wong TY, Foster PJ, Johnson GJ, Seah SK. Education, socioeconomic status, and ocular dimensions in Chinese adults: the Tanjung Pagar Survey. Br J Ophthalmol. 2002;86:963–8.

84. Lee KE, Klein BE, Klein R, Quandt Z, Wong TY. Association of age, stature, and education with ocular dimensions in an older white population. Arch Ophthalmol. 2009;127:88–93.

85. Hou L, Bergen SE, Akula N, Song J, Hultman CM, Landen M, et al. Genome-wide association study of 40,000 individuals identifies two novel loci associated with bipolar disorder. Hum Mol Genet. 2016;25:3383–94.

86. Glahn DC, Bearden CE, Bowden CL, Soares JC. Reduced educational attainment in bipolar disorder. J Affect Disord. 2006;92:309–15.

87. Hagenaars SP, Harris SE, Davies G, Hill WD, Liewald DC, Ritchie SJ, et al. Shared genetic aetiology between cognitive functions and physical and mental health in UK Biobank (N=112,151) and 24 GWAS consortia. Mol Psychiatry. 2016;21:1624–32.

88. Power RA, Steinberg S, Bjornsdottir G, Rietveld CA, Abdellaoui A, Nivard MM, et al. Polygenic risk scores for schizophrenia and bipolar disorder predict creativity. Nat Neurosci. 2015;18:953–5.

89. Nelson PT, Estus S, Abner EL, Parikh I, Malik M, Neltner JH, et al. ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology. Acta Neuropathol. 2014;127:825–43.
A decade in psychiatric GWAS research

96. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303:1832–40.

97. Perez-Palma E, Bustos BI, Villaman CF, Alcaron MA, Avila ME, Ugarte GD, et al. Overrepresentation of glutamate signaling in Alzheimer’s disease: network-based pathway enrichment using meta-analysis of genome-wide association studies. PLoS ONE. 2014;9:e95413.

98. Heinzen EL, Need AC, Hayden KM, Chiba-Falek O, Roses AD, Strittmatter WJ, et al. Genome-wide scan of copy number variation in late-onset Alzheimer’s disease. J Alzheimers Dis. 2010;19:69–77.

99. Harold D, Abraham R, Hollingsworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet. 2009;41:1088–93.

100. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet. 2009;41:1094–9.

101. Naj AC, Beecham GW, Martin ER, Gallins PJ, Powell EH, Konidari I, et al. Dementia revealed: novel chromosome 6 locus for late-onset Alzheimer disease provides genetic evidence for folate-pathway abnormalities. PLoS Genet. 2010;6:e1001130.

102. Davies G, Harris SE, Reynolds CA, Payton A, Knight HM, Clarke R, et al. Newly identified loci that influence lipid concentrations: a florbetapir PET genome-wide association study. Mol Psychiatry. 2014;19:351–7.

103. Herold C, Hooli BV, Mullin K, Liu T, Roehr JT, Mattheisen M, et al. Family-based association analyses of imputed genotypes reveal genome-wide significant association of Alzheimer’s disease with OSBP6L1, PTPRG, and PDCL3. Mol Psychiatry. 2016;21:1608–12.

104. Kamboh MI, Demiric FY, Wang X, Minster RL, Carrascoillo MM, Pankratz VS, et al. Genome-wide association study of Alzheimer’s disease. Transl Psychiatry. 2012;2:e117.

105. De Jager PL, Shulman JM, Chibnik LB, Keenan BT, Raj T, Wilson RS, et al. A genome-wide scan for common variants affecting the rate of age-related cognitive decline. Neurobiol Aging. 2012;33:1017 e1011–5.

106. Aluchenko YS, Ripatti S, Lindqvist I, Boomsma D, Heid IM, Pramstaller PP, et al. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet. 2009;41:47–55.

107. Feulner TM, Law SM, Friedrich P, Wagenpfeil S, Wurst SH, Riehle C, et al. Examination of the current top candidate genes for AD in a genome-wide association study. Mol Psychiatry. 2010;15:756–66.

108. Antunec M, Boada M, Gonzalez-Perez A, Gayan J, Ramirez-Lorca R, Marin J, et al. The membrane-spanning 4-domains, subfamily A (MS4A) gene cluster contains a common variant associated with Alzheimer’s disease. Genome Med. 2011;3:33.

109. Li J, Zhang Q, Chen F, Yan J, Kim S, Wang L, et al. Genetic interactions explain variance in circulate amyloid burden: an AV-45 PET genome-wide association and interaction study in the ADNI cohort. Biomed Res Int. 2015;2015:647389.

110. Kristiansson K, Perola M, Tikkanen E, Kettunen J, Surakka I, Havulinna AS, et al. Genome-wide screen for metabolic syndrome susceptibility loci reveals strong lipid gene contribution but no evidence for common genetic basis for clustering of metabolic syndrome traits. Circ Cardiovasc Genet. 2012;5:242–9.

111. Hollingworth P, Sweet R, Sims R, Harold D, Russo G, Abraham R, et al. Genome-wide association study of Alzheimer’s disease with psychotic symptoms. Mol Psychiatry. 2012;17:1316–27.

112. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518:197–206.

113. Dorajoo R, Li R, Ikram MK, Liu J, Fugroel P, Lee J, et al. Are C-reactive protein associated genetic variants associated with serum levels and retinal markers of microvascular pathology in Asian populations from Singapore? PLoS ONE. 2013;8:e67650.

114. Schott JM, Crutch SJ, Carrasquillo MM, Uphill J, Shakespeare TJ, Ryan NS, et al. Genetic risk factors for the posterior cortical atrophy variant of Alzheimer’s disease. Alzheimers Dement. 2016;12:862–71.

115. Fritsche LG, Igl W, Bailey JM, Grassmann F, Sengupta S, Bragg-Gresham JL, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet. 2016;48:134–43.

116. Ramanan VK, Risacher SL, Nho K, Kim S, Swaminathan S, Shen L, et al. APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study. Mol Psychiatry. 2014;19:351–7.

117. Shen L, Kim S, Risacher SL, Nho K, Swaminathan S, West JD, et al. Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: a study of the ADNI cohort. Neuroimage. 2010;53:1051–63.

118. Ramirez A, van der Flier WM, Herold C, Ramonet D, Heilmann S, Lewczuk P, et al. SCUL2G2 identified as both a determinant of CSF Abeta1–42 levels and an attenuator of cognitive decline in Alzheimer’s disease. Hum Mol Genet. 2014;23:6644–58.

119. Beecham GW, Hamilton K, Naj AC, Martin ER, Huertelman MA, Myers AJ, et al. Genome-wide association meta-analysis of neuropathologic features of Alzheimer’s disease and related dementias. PLoS Genet. 2014;10:e1004606.

120. Fritsche LG, Chen W, Schu M, Yasp BL, Yu Y, Thorleifsson G, et al. Seven new loci associated with age-related macular degeneration. Nat Genet. 2013;45:433–9. 439 ee431–432

121. Ligthart S, Vaez A, Hsu YH, Inflammation Working Group of the CC, PMI WG, XCP, LifeLines Cohort S, et al. A comprehensive 1000 genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet. 2015;47:1121–30.

122. Sandhu MS, Waterworth DM, Debenham SL, Wheeler E, Papadakis K, Zhao JH, et al. LDL-cholesterol concentrations: a genome-wide association study. Lancet. 2008;371:483–91.

123. Waterworth DM, Ricketts SL, Song K, Chen L, Zhao JH, Ripatti S, et al. Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arterioscler Thromb Vasc Biol. 2010;30:2264–76.

124. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet. 2008;40:161–9.

125. Keller M, Schleinitz D, Forster J, Tonjes A, Bottcher Y, Fischer-Malieskewitz F, et al. Eight genetic loci associated with variation in lipoprotein metabolism yield new insights into obesity biology. Nature. 2015;518:197–206.

126. Grallert H, Dupuis J, Bis JC, Dehghan A, Barbalic M, Baumert J, et al. Seven new loci associated with age-related macular degeneration. Nat Genet. 2013;45:433–9. 439 ee431–432

127. Grallert H, Dupuis J, Bis JC, Dehghan A, Barbalic M, Baumert J, et al. Seven new loci associated with age-related macular degeneration. Nat Genet. 2013;45:433–9. 439 ee431–432

128. Suchindran S, Rivedal D, Guyton JR, Milledge T, Gao X, Benjamion A, et al. Genome-wide association study of Lp-PLA2 activity and mass in the Framingham Heart Study. PLoS Genet. 2010;6:e1000928.
